North Shields, United Kingdom Clinical Trials
A listing of North Shields, United Kingdom clinical trials actively recruiting patients volunteers.
Found (11) clinical trials
Efficacy Study for Geko Device in VLU Patients
Screen patient database to identify eligible patients Obtain informed consent and inform participant's GP Complete CRF throughout the study period (demographics, vital signs, medical history, study ulcer history, concomitant medication) Physical examination at the study start up visit and at consecutive weekly visits Take a digital image of the wound ...
3.02 miles
BioVentrix Revivent TC System Clinical Study
The Revivent TC System is indicated for patients referred for surgical treatment of left ventricular scar that is contiguous, and includes both anterior and septal components. Primary and Secondary Effectiveness Endpoints will compare data from the patients treated with the Revivent TC System to a control pool of patients who ...
5.74 miles
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
PATHOS is a multicentre, open label, parallel group Phase II/III randomised controlled trial (RCT). Approximately 242 patients will be recruited to the phase II study. Patients eligible for the study must have biopsy proven oropharyngeal squamous cell carcinoma (OPSCC) clinically staged T1T3 N0N2b. Their primary tumour, as judged by the ...
5.74 miles
European Trial of Pirfenidone in BOS A European Multi-center Study
Title of the study: A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients Study design: Randomized double blinded, placebo controlled study. Eligible patients are to be randomized in a 1:1 ratio to receive either Pirfenidone 2403 mg/d or the matching placebo treatment ...
5.74 miles
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10 patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial). Phase III: to determine whether the 5-year disease-free survival rate among patients who do not have ...
5.74 miles
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Primary To evaluate the long-term safety and tolerability of seladelpar Secondary To evaluate the long-term efficacy of seladelpar
7.03 miles
Pressure Wire Guided Cardiac Resynchronisation Therapy
Heart failure patients may benefit from having a special pacemaker implanted that can make the heart pump in a more coordinated and efficient way Cardiac Resynchronisation Therapy (CRT). For the heart to pump well it is necessary for the pacing wires to be placed in optimal positions. Only two thirds ...
7.05 miles
Safety Pharmacokinetics and Efficacy of Dupilumab in Patients 6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
Part A (open-label, single-ascending-dose, sequential cohort phase 2 study): Primary objective is to characterize the safety and PK of dupilumab administered as a single dose in pediatric participants, 6 months to less than 6 years of age, with severe AD. Secondary objective is to evaluate the efficacy and immunogenicity of ...
7.05 miles
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
This is a randomized, placebo-controlled, double-blind dose range study in autoimmune hepatitis. The study population consists of female and male adult autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care. The diagnosis of autoimmune hepatitis has to fulfill the IAIHG criteria and must be confirmed by ...
7.08 miles
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to ...
7.08 miles